fashion -WSS

fashion

author：knowledge 2025-09-28 15:20:51 - browse：99

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Health Care Service Corp to buy Cigna Medicare Advantage plans

hotspot

WSS

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

Humana’s losses in Medicare Advantage tank its stock

Elizabeth Holmes on track for early release from her 11

Reconstructing family trees of blood cells may help predict disease

California’s proposed $25 per hour health care minimum wage

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

focus

fashion

leisure time

Jerome Adams on the need for new antivirals for Covid

How generative AI ratchets up security threats for health systems

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

It's time to get medical device identifiers over the finish line

New air purifier tech could be key to improving indoor air quality

Medicare drug price negotiation legal challenge met with skepticism

Alkermes shareholders re

White House pharmacy plagued with problems, investigation finds

In age of alternative facts, a scholarly course on calling out crap

Why Medicare shouldn’t cover every FDA

focus

Bernie Sanders is gearing up to subpoena pharma CEOs

FTC sues over Novant Health acquisition of two N.C. hospitals

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Health Care Service Corp to buy Cigna Medicare Advantage plans

N.Y. state detects polio case, first in the U.S. since 2013

Iowa House, Senate pass 6

Wikipedia

hotspot

hotspot

leisure time